Follows adults with psoriasis who switch from ustekinumab to guselkumab
Studies how guselkumab works in adults with psoriasis switched from ustekinumab.
Plain-language title generated from the registry record
Registry title: A Study of Guselkumab Given After Ustekinumab in Participants With Moderate to Severe Psoriasis in Routine Clinical Practice
Key facts
- Where
- Budapest, HungarySee the site
Where in Hungary
- Semmelweis UniversityBudapest, HungaryTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Janssen-Cilag Kft.
- Trial code
- NCT07746583
- Record updated
- 3 November 2026
- Original description
The main purpose of this study is to describe how well Guselkumab works after switching from Ustekinumab in participants with moderate to severe psoriasis in a routine clinical setting. A long-term skin disease that causes red, scaly and sometimes painful, itchy patches on the skin.Read full original descriptionShow less
A Non-Interventional, Multi-Centric, Single Country Observational Study to Assess the Safety and Effectiveness of Guselkumab After Ustekinumab (Originator or Biosimilar) in Moderate to Severe Psoriasis Patients in Clinical Routine
The main purpose of this study is to describe how well Guselkumab works after switching from Ustekinumab in participants with moderate to severe psoriasis in a routine clinical setting. A long-term skin disease that causes red, scaly and sometimes painful, itchy patches on the skin.
Inclusion: Must have a confirmed diagnosis of moderate-to-severe plaque psoriasis requiring systemic treatment; Participants who are currently being treated with Ustekinumab (either the originator or its biosimilar) and who are medically indicated to switch to Guselkumab, or for whom this switch is medically indicated, based on the current and valid national psoriasis (PsO) therapeutic protocol; Participants who, based on the Investigator's decision, should initiate treatment with Guselkumab; Participants must sign an informed consent form (ICF) allowing for data collection and source data verification in accordance with local requirements.
Exclusion: Previous use of guselkumab in any indication in participant history; Contraindication or hypersensitivity to Guselkumab or any other ingredient in the injection solution; Pregnancy or breastfeeding; Currently enrolled in an interventional study; Currently enrolled in an observational study sponsored or managed by a Janssen company.